DK0792643T3 - Anvendelse af en aldosereduktaseinhibitor til at reducere skade på ikke-cardialt væv - Google Patents
Anvendelse af en aldosereduktaseinhibitor til at reducere skade på ikke-cardialt vævInfo
- Publication number
- DK0792643T3 DK0792643T3 DK97301172T DK97301172T DK0792643T3 DK 0792643 T3 DK0792643 T3 DK 0792643T3 DK 97301172 T DK97301172 T DK 97301172T DK 97301172 T DK97301172 T DK 97301172T DK 0792643 T3 DK0792643 T3 DK 0792643T3
- Authority
- DK
- Denmark
- Prior art keywords
- tissue damage
- reductase inhibitor
- cardiac tissue
- aldose reductase
- reduce non
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01021—Aldehyde reductase (1.1.1.21), i.e. aldose-reductase
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1270796P | 1996-02-29 | 1996-02-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0792643T3 true DK0792643T3 (da) | 2002-07-22 |
Family
ID=21756300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK97301172T DK0792643T3 (da) | 1996-02-29 | 1997-02-21 | Anvendelse af en aldosereduktaseinhibitor til at reducere skade på ikke-cardialt væv |
Country Status (14)
Country | Link |
---|---|
US (1) | US6127367A (de) |
EP (1) | EP0792643B1 (de) |
JP (1) | JPH09316003A (de) |
KR (1) | KR970061252A (de) |
CN (1) | CN1081460C (de) |
AT (1) | ATE216239T1 (de) |
AU (1) | AU724327B2 (de) |
CA (1) | CA2198564C (de) |
DE (1) | DE69711972T2 (de) |
DK (1) | DK0792643T3 (de) |
ES (1) | ES2172748T3 (de) |
IL (1) | IL120264A0 (de) |
PT (1) | PT792643E (de) |
ZA (1) | ZA971717B (de) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0982306A3 (de) * | 1998-08-21 | 2000-07-05 | Pfizer Products Inc. | Polymorph von Zopolrestat Monohydrat |
US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
WO2002098421A1 (en) * | 2001-06-05 | 2002-12-12 | University Of Maryland, Baltimore | Novel treatment for neurological and psychiatric disorders |
DE60335359D1 (de) | 2002-04-30 | 2011-01-27 | Kudos Pharm Ltd | Phthalazinonderivate |
GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
US20110092566A1 (en) * | 2004-11-19 | 2011-04-21 | Srivastava Satish K | Treatment of cancer with aldose reductase inhibitors |
GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
ES2393271T3 (es) * | 2005-12-16 | 2012-12-19 | Sanwa Kagaku Kenkyusho Co., Ltd | Agente para la prevención y tratamiento de la insuficiencia renal aguda |
WO2007097301A1 (ja) * | 2006-02-20 | 2007-08-30 | Sanwa Kagaku Kenkyusho Co., Ltd. | 脳卒中における脳虚血又は脳虚血再灌流障害の予防又は治療剤 |
UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
ES2409930T3 (es) * | 2007-01-31 | 2013-06-28 | Sanwa Kagaku Kenkyusho Co., Ltd | Agente protector del nervio de la retina o del nervio óptico |
US8273746B2 (en) * | 2007-03-23 | 2012-09-25 | The Board Of Regents Of The University Of Texas System | Methods involving aldose reductase inhibitors |
CN101809017A (zh) | 2007-09-14 | 2010-08-18 | 阿斯利康(瑞典)有限公司 | 酞嗪酮衍生物 |
KR101598231B1 (ko) | 2007-10-17 | 2016-02-26 | 쿠도스 파마슈티칼스 리미티드 | 4-[3-(4-시클로프로판카르보닐-피페라진-1-카르보닐)-4-플루오로-벤질]-2h-프탈라진-1-온 |
EP2220216A4 (de) * | 2007-11-15 | 2013-03-20 | Univ Laval | Verfahren zur regulation der prostaglandin f-synthase- (pgfs-)aktivität von akr1b1 und verwendungen davon |
AR070221A1 (es) | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
US20090270490A1 (en) * | 2008-04-24 | 2009-10-29 | The Board Of Regents Of The University Of Texas System | Methods involving aldose reductase inhibition |
EP2346495B2 (de) | 2008-10-07 | 2023-05-24 | Kudos Pharmaceuticals Limited | Pharmazeutische formulierung 514 |
WO2012088525A2 (en) | 2010-12-23 | 2012-06-28 | The Board Of Regents Of The University Of Texas System | Methods for treating copd |
US10443185B2 (en) | 2016-10-19 | 2019-10-15 | Spectrum Brands, Inc. | Portable steam generator base for iron |
US20240033263A1 (en) | 2021-03-18 | 2024-02-01 | Banavara MYLARI | Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications |
WO2024053761A1 (ko) * | 2022-09-07 | 2024-03-14 | 애니머스큐어 주식회사 | 알도오즈 환원효소 억제제를 포함하는 근원 세포 증식 및 분화 촉진용 조성물 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4492706A (en) * | 1983-08-01 | 1985-01-08 | American Home Products Corporation | Method of lowering lipid levels |
US4939140A (en) * | 1985-11-07 | 1990-07-03 | Pfizer Inc. | Heterocyclic oxophthalazinyl acetic acids |
EP0310931A3 (de) * | 1987-10-08 | 1990-10-03 | Ethyl Corporation | Hühnerfutter |
FR2665440B1 (fr) * | 1990-07-31 | 1994-02-04 | Lipha | Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant. |
US5064830A (en) * | 1990-08-02 | 1991-11-12 | Pfizer Inc. | Lowering of blood uric acid levels |
JP3049284B2 (ja) * | 1990-11-07 | 2000-06-05 | 株式会社三和化学研究所 | ヒダントイン誘導体並びにそれを有効成分とする糖尿病合併症及び循環器系疾患の予防及び治療剤 |
US5391551A (en) * | 1993-05-10 | 1995-02-21 | Pfizer Inc. | Method of lowering blood lipid levels |
AU711080B2 (en) * | 1994-12-22 | 1999-10-07 | Regents Of The University Of California, The | Method for protecting the heart from ischemia |
US5834466A (en) * | 1994-12-22 | 1998-11-10 | The Regents Of The University Of California | Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia |
IL118474A (en) * | 1995-06-01 | 2001-08-08 | Sankyo Co | Benzimideol derivatives and pharmaceutical preparations containing them |
-
1997
- 1997-02-20 IL IL12026497A patent/IL120264A0/xx not_active IP Right Cessation
- 1997-02-20 US US08/803,301 patent/US6127367A/en not_active Expired - Fee Related
- 1997-02-21 EP EP97301172A patent/EP0792643B1/de not_active Expired - Lifetime
- 1997-02-21 AT AT97301172T patent/ATE216239T1/de not_active IP Right Cessation
- 1997-02-21 DK DK97301172T patent/DK0792643T3/da active
- 1997-02-21 PT PT97301172T patent/PT792643E/pt unknown
- 1997-02-21 ES ES97301172T patent/ES2172748T3/es not_active Expired - Lifetime
- 1997-02-21 DE DE69711972T patent/DE69711972T2/de not_active Expired - Fee Related
- 1997-02-24 JP JP9039071A patent/JPH09316003A/ja active Pending
- 1997-02-26 CA CA002198564A patent/CA2198564C/en not_active Expired - Fee Related
- 1997-02-27 CN CN97102574A patent/CN1081460C/zh not_active Expired - Fee Related
- 1997-02-27 ZA ZA971717A patent/ZA971717B/xx unknown
- 1997-02-28 AU AU15010/97A patent/AU724327B2/en not_active Ceased
- 1997-02-28 KR KR1019970006780A patent/KR970061252A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IL120264A0 (en) | 1997-06-10 |
EP0792643A1 (de) | 1997-09-03 |
PT792643E (pt) | 2002-08-30 |
DE69711972D1 (de) | 2002-05-23 |
MX9701533A (es) | 1998-06-30 |
US6127367A (en) | 2000-10-03 |
JPH09316003A (ja) | 1997-12-09 |
AU1501097A (en) | 1997-09-04 |
CA2198564A1 (en) | 1997-08-29 |
AU724327B2 (en) | 2000-09-14 |
ZA971717B (en) | 1998-08-27 |
DE69711972T2 (de) | 2002-08-29 |
KR970061252A (ko) | 1997-09-12 |
EP0792643B1 (de) | 2002-04-17 |
CN1081460C (zh) | 2002-03-27 |
CA2198564C (en) | 2000-06-27 |
ATE216239T1 (de) | 2002-05-15 |
ES2172748T3 (es) | 2002-10-01 |
CN1168794A (zh) | 1997-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0792643T3 (da) | Anvendelse af en aldosereduktaseinhibitor til at reducere skade på ikke-cardialt væv | |
TR200200129T2 (tr) | Hepatit C inhibitörü tri-peptidler | |
BR9707791A (pt) | Corpo ótico | |
BR9707766A (pt) | Corpo ótico | |
DE69902953D1 (de) | Optischer Kopf | |
FI953592A (fi) | 2-(2-amino-1,6-dihydro-6-oksopurin-9-yyli)metoksi-1,3-propaanidiolijohdannainen | |
DE69832431D1 (de) | N-Weg-RF-Leistungsaddierer/-verteiler | |
NO985497D0 (no) | Trykkf°lsomt br°nnverkt°y med en mellomtrinn-trykkstilling | |
DE50011290D1 (de) | Strukturbauteil | |
DE60023852D1 (de) | Objektivlinse | |
DE69932138D1 (de) | Optischer Kopf | |
ID17448A (id) | Pelepas hubungan sel mini | |
ITMI930499V0 (it) | Sottopiede ad elevate prestazioni tecniche | |
DE69726053D1 (de) | Optischer Kopf | |
DK0791355T3 (da) | Fremgangsmåde til reduktion af vævsbeskadigelse forbundet med iskæmi | |
DE69717571T2 (de) | Optischer Kopf | |
KR930024341U (ko) | 리미트 스위치의 파손 방지용 레버 | |
KR940023766U (ko) | 휴대용 이어폰의 엉킴방지용 부착구 | |
WO2001046421A3 (en) | Zcys5: a member of the cystatin superfamily | |
GB0200357D0 (en) | Monolithic waveguide polarisation beam splitter | |
SE9401722D0 (sv) | Aktiv reflex med optiskt våglängdsområde |